Helena Yu
MD
Associate Attending Physician
👥Biography 个人简介
Helena Yu investigates HER2 exon 20 insertion mutations in NSCLC and has contributed to pivotal trials of trastuzumab deruxtecan and emerging HER2-selective tyrosine kinase inhibitors. Her work defines molecular subsets and resistance mechanisms within HER2-altered NSCLC. She leads early-phase clinical development for novel HER2 agents.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Helena Yu 的研究动态
Follow Helena Yu's research updates
留下邮箱，当我们发布与 Helena Yu（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment